JAKi are immunomodulators that target one or more enzymes in the JAK family, thereby affecting the JAK/signal transducer and activator of transcription (STAT) pathway.4 The JAK/STAT pathway is involved in fibrosis, inflammation, and angiogenesis through cytokines including IL-4, 10, 13, 6, and interferon α, β, and γ.4 It is therefore postulated that the anti-inflammatory and antifibrotic properties of JAKi may be beneficial for SSc management.5 The gene discussed is SOAT1; the disease is systemic sclerosis.